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Abstract
99mTc-HYNIC-annexin A5 can be considered as a benchmark in the field of apoptosis imaging. However, 99mTc-HYNIC-
annexin A5 has characteristics of high uptake and long retention in non-target tissues such as kidney and liver. To minimize
this problem, we developed a novel 99mTc-labeled annexin A5 using a bis(hydroxamamide) derivative [C3(BHam)2] as a
bifunctional chelating agent, and evaluated its usefulness as an imaging agent for detecting apoptosis. The amino group of
C3(BHam)2 was converted to a maleimide group, and was coupled to thiol groups of annexin A5 pretreated with 2-
iminothiolane. 99mTc labeling was performed by a ligand exchange reaction with 99mTc-glucoheptonate. Biodistribution
experiments for both 99mTc-C3(BHam)2-annexin A5 and
99mTc-HYNIC-annexin A5 were performed in normal mice. In
addition, in tumor-bearing mice, the relationship between the therapeutic effects of chemotherapy (5-FU) and the tumor
accumulation of 99mTc-C3(BHam)2-annexin A5 just after the first treatment of 5-FU was evaluated.
99mTc-C3(BHam)2-annexin
A5 was prepared with a radiochemical purity of over 95%. In biodistribution experiments, 99mTc-C3(BHam)2-annexin A5 had
a much lower kidney accumulation of radioactivity than 99mTc-HYNIC-annexin A5. In the organs for metabolism, such as liver
and kidney, radioactivity after the injection of 99mTc-HYNIC-annexin A5 was residual for a long time. On the other hand,
radioactivity after the injection of 99mTc-C3(BHam)2-annexin A5 gradually decreased. In therapeutic experiments, tumor
growth in the mice treated with 5-FU was significantly inhibited. Accumulation of 99mTc-C3(BHam)2-annexin A5 in tumors
significantly increased after 5-FU treatment. The accumulation of radioactivity in tumor correlated positively with the counts
of TUNEL-positive cells. These findings suggest that 99mTc-C3(BHam)2-annexin A5 may contribute to the efficient detection
of apoptotic tumor response after chemotherapy.
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Introduction
Annexin A5 is a 36-kDa human protein with a high affinity for
phosphatidyl serine (PS). PS is normally retained on the
intracellular face of the cell membrane. However, when cells
undergo apoptosis (cell death), this distribution is altered, that is,
PS is rapidly exposed to the outside of the cell membrane. For that
reason, radiolabeled annexin A5 can be used to detect cell death in
vivo [1,2].
99mTc is an ideal radionuclide for scintigraphic imaging
applications due to its excellent physical properties, low cost,
and ready availability because of generator-produced nuclide.
Since most polypeptides do not possess binding sites to form 99mTc
chelates of high in vivo stability, appropriate chelating molecules
are incorporated into polypeptide molecules to prepare 99mTc-
labeled peptides for in vivo applications. Hydrazinonicotinamide
(HYNIC) is one of the most attractive bifunctional chelating agents
for the labeling of peptides and proteins with 99mTc. It was
reported that HYNIC acts as a monodentate or bidentate ligand to
form a mixed ligand 99mTc complex in the presence of appropriate
coligands [3]. Several coligands have been reported such as
glucoheptonate, tricine, ethylene diamine diacetic acid (EDDA),
and ternary ligand systems containing tricine and water-soluble
phosphines or tricine and imine-N-containing heterocycles.
Tricine has been used most widely for protein labeling, since it
provides 99mTc-HYNIC-labeled polypeptides with high radio-
chemical yields and high specific activities in a short reaction time
[4,5]. 99mTc-HYNIC-annexin A5 can be considered as a
benchmark in the field of apoptosis imaging since this tracer is
the most extensively investigated and best characterized apoptosis-
detecting radioligand to date [6]. Although 99mTc-HYNIC-
annexin A5 has been successfully used in many studies, it has
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characteristics of high uptake and long retention in non-target
tissues such as kidney and liver [7].
On the other hand, bis(hydroxamamide) derivative, N,N’-
trimethylenedibenzohydroxamamide ligand [C3(BHam)2] can also
form a stable 99mTc complex over a wide pH range under mild
reaction conditions within short reaction times [8]. The complex-
ation yield is high (over 95%) at ligand concentrations as low as
2.561026 M. In a previous study, when 99mTc-C3(BHam)2-IgG
was administered to mice, the radioactivity in liver was not
residual [9]. This result suggests that the radiometabolite of 99mTc-
C3(BHam)2-IgG could be eliminated rapidly from metabolic
organs.
The aim of this study is to develop and evaluate a novel 99mTc-
labeled annexin A5, which shows lower the radioactivity levels in
non-target tissue, such as kidney and liver. Then, we assumed that
the clearance of radiometabolites in these organs might play a
crucial role, and hypothesized that the radioactivity after
administration of 99mTc-C3(BHam)2-conjugated annexin A5,
99mTc-C3(BHam)2-annexin A5, could be rapidly eliminated from
kidney and liver. 99mTc-C3(BHam)2-annexin A5 was prepared and
its bioactivity and biodistribution was compared to that of 99mTc-
HYNIC-annexin A5. In addition, to evaluate whether 99mTc-
C3(BHam)2-annexin A5 is able to detect apoptosis as an early
response of chemotherapy, the relationship between the thera-
peutic effects of chemotherapy and the tumor accumulation of
99mTc-C3(BHam)2-annexin A5 after injection of 5-FU in tumor-
bearing mice, and the correlation between tumor accumulation or
intratumoral distribution of 99mTc-C3(BHam)2-annexin A5 and
the number of TUNEL-staining positive cells were evaluated.
Materials and Methods
Materials
Thin layer chromatography (TLC) analyses were performed
with silica plates (Silica gel 60, Merck KGaA, Darmstadt,
Germany) with saline as a developing solvent. Size-exclusion
(SE)-HPLC analyses were performed with a TSK-GEL Super
SW3000 column (4.66300 mm, TOSOH, Tokyo, Japan) at a flow
rate of 0.3 mL/min with 0.1 M phosphate buffer (pH 6.8).
[99mTc]Pertechnetate (99mTcO4
-) was eluted in saline solution
from generators (Nihon Medi-Physics Co., Ltd., Tokyo, Japan).
Annexin A5 was generously provided by Kowa Co., Ltd. (Nagoya,
Japan). Other reagents were of reagent grade and used as received.
Preparation of C3(BHam)2-annexin A5
C3(BHam)2-Annexin A5 (7) was prepared according to the
procedure outlined in Figure 1.
49-Aminomethyl-N,N9-trimethylenedibenzohydroxamamide
[NH2-C3(BHam)2] (1) was prepared according to a previously
reported procedure [9]. Compound 1 (1 mg) was dissolved in
36 mL of N,N-dimethylformamide (DMF), and N-(6-maleimidoca-
proyloxy)succinimide (EMCS) (2), dissolved in 36 mL of DMF, was
added to the solution of compound 1. Annexin A5 (2 mg) was
dissolved in 800 mL of 0.16 M borate buffer containing 2 mM
EDTA (pH 8.0). 2-Iminothiolane (2-IT) (5) (80 mg) dissolved in
40 mL of 0.16 M borate buffer containing 2 mM EDTA (pH 8.0)
was added to the annexin A5 solution. After being stirred for 1 h
at room temperature, the reaction mixture was purified by PD-10
column (GE Healthcare UK Ltd., Buckinghamshire, England).
The fraction (1.5 mL) containing 2-iminothiolane conjugated
annexin A5 (6) was determined by SE-HPLC monitoring of UV
adsorption at a wavelength of 280 nm, and collected. An aqueous
solution of 1 M NaH2PO4 (192 mL) and 16 mL of the reaction
mixture (3) described above was added to the compound 6
solution (1.5 mL), and the reaction mixture was stirred for 2 h at
room temperature. After addition of 100 mL of iodoacetamide
(10 mg/mL) to alkylate the unreacted thiol groups, the solution
was further gently agitated for 10 min. The C3(BHam)2-annexin
A5 (7) conjugate was separated from unreacted small molecules by
PD-10 column. The number of C3(BHam)2 ligands introduced per
molecule of annexin A5 was estimated by measuring the number
of thiol groups in the annexin A5 before and after the conjugation
reaction with compound 3 using 4,49-dithiodipyridine [10].
99mTc Labeling of C3(BHam)2-annexin A5
C3(BHam)2-Annexin A5 was labeled with
99mTc by a ligand-
exchange reaction with 99mTc-glucoheptonate.
99mTcO4
- (100L, 37-740 MBq) was added to 0.2 mg of
lyophilized Sn(II) glucoheptonate, which was prepared by the
method described previously by Yamamura et al [11], and allowed
to stand for 15 min at room temperature. Formation of 99mTc-
glucoheptonate was ascertained by TLC developed with acetone.
The 99mTc-glucoheptonate solution was added to the C3(BHam)2-
annexin A5 solution (334–1407 mg/mL) and the mixture was
incubated for 1 h at room temperature. The radiochemical
purities of 99mTc-C3(BHam)2-annexin A5 were determined by
TLC and SE-HPLC. When the radiochemical purity was less than
95%, the reaction mixture was purified with a PD-10 column with
saline as the eluate.
Cell Binding Assay
The bioactivity of 99mTc-labeled annexin A5 was determined by
their binding to erythrocytes, according to a previously reported
procedure [12]. In brief, 99mTc-C3(BHam)2-annexin A5 or
99mTc-
HYNIC-annexin A5, which was prepared according the previ-
ously reported procedure [7], at 10 nmol/L final concentration
was added to duplicated tubes containing a final volume of 1 mL
of buffer HNKGB (10 mM HEPES-Na, pH 7.4, 136 mM NaCl,
2.7 mM KCl, 5 mM glucose, and 1 mg/mL BSA) plus 2.5 mmol/
L CaCl2. One tube then received 4.2610
8 erythrocytes in 100 mL.
The other tube then received an equal volume of buffer, and
samples were incubated for 15 min at room temperature. After
centrifugation at 8,320 g for 3 min, the radioactivity of the
supernatant was measured with an auto well gamma counter
(ARC-380; Aloka, Tokyo, Japan). The binding ratios were
determined as follows: Radioactivity bound to erythrocytes
(%) = (1 – [radioactivity of supernatant in the presence of
erythrocytes]/[radioactivity of supernatant in absence of erythro-
cytes]) 6100.
Biodistribution Experiments
The animal experimental protocols used were approved by the
Committee on Animal Experimentation of Kanazawa University
(Permit Number: AP-132633). Experiments with animals were
conducted in strict accordance with the Guidelines for the Care
and Use of Laboratory Animals of Kanazawa University. The
animals were housed with free access to food and water at 23uC
with a 12-hour alternating light/dark schedule. Biodistribution
experiments were performed by intravenous administration of
100 mL of 99mTc-labeled Annexin A5 (37 kBq, 1.5 mg Annexin
A5) into 6-week-old male ddY mice (28–30 g, Japan SLC, Inc.,
Hamamatsu, Japan). Groups of five mice each were sacrificed by
decapitation at 10 min, 1, 3, and 6 h after injection. Organs of
interest were removed and weighed and the radioactivity counts
were determined with an auto well gamma counter and corrected
for background radiation and physical decay during counting.
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Preparation of Tumor-Bearing Mice and Chemotherapy
Colon-26, a colorectal adenocarcinoma cell line derived from
BALB/c mice, was used (TKG 0518, Cell Resource Center for
Biomedical Research, Tohoku University, Sendai, Japan) [13]. To
produce tumors, approximately 36106 of the prepared colon-26
cells in HEPES-buffered saline solution with 1% methylcellulose
were injected subcutaneously into the dorsum of 6-week-old
female BALB/c mice (15–20 g, Japan SLC, Inc.).
The mice were randomly distributed in the experimental
groups. At 6 and 13 days after inoculation of the tumor cells, 5-
fluorouracil (5-FU, Nacalai Tesque, Kyoto, Japan) was injected
intraperitoneally at a dose of 100 mg/kg or 150 mg/kg. A group
of saline-injected mice served as an untreated control group.
Tumor size was measured with a slide caliper in two dimensions
three times per week. Individual tumor volumes (V) were
calculated by the formula V = [length6(width)263.14]/6 and
compared with the values on the day of treatment (relative tumor
volume).
Evaluation of Tumor Uptake of 99mTc-C3(BHam)2-annexin
A5 and 99mTc-HYNIC-annexin A5
At 6 days after inoculation of the colon-26 tumor cells into the
mice, 5-FU was injected intraperitoneally at a dose of 100 mg/kg
or 150 mg/kg. A group of saline-injected mice served as a control
group. At 24 h after treatment of 5-FU, 99mTc-C3(BHam)2-
annexin A5 (37 kBq, 1.5 mg annexin A5) was administered
intravenously into the tumor-bearing mice. In the case of 99mTc-
HYNIC-annexin A5, a 150 mg/kg of 5-FU treated group and a
control group were used. The mice were sacrificed by decapitation
at 4 h after injection of 99mTc-C3(BHam)2-annexin A5 or
99mTc-
HYNIC-annexin A5. The tumors were removed and weighed and
the radioactivity counts were determined with an auto well gamma
counter. After the counts were determined, the tumors were
embedded in Tissue-TekH O.C.T. compound medium (Sakura
Finetek USA, Inc., Torrance, CA, USA) and frozen. Tumor
sections 8 mm in size were obtained using a cryostat (HM 525
Cryostat, Thermo Fisher Scientific Inc., Waltham, MA, USA) for
histological analysis.
TUNEL Staining
Tumor sections were stained with terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick-end labeling
(TUNEL) using a commercially available kit (In situ Apoptosis
Detection Kit, Takara Bio Inc., Otsu, Japan) according to the
manufacturer’s protocol. TUNEL-stained tissue sections were
observed under a fluorescence microscope (BZ-9000, Keyence,
Osaka, Japan). The number of TUNEL-positive cells was counted
on 10 randomly chosen fields for each section.
Ex Vivo Autoradiographic Experiments
99mTc-C3(BHam)2-annexin A5 (11.1 MBq) was intravenously
administered to 5-FU (150 mg/kg) treated tumor bearing mice or
non-treatment tumor bearing mice as a control group, which were
prepared by the above-mentioned method. At 4 hours after
injection of 99mTc-C3(BHam)2-annexin A5, the tumors were
removed, embedded in Tissue-TekH O.C.T. compound medium,
and frozen. Serial frozen sections 8 mm in size were obtained using
a cryostat. The sections were exposed for 12 hours on an imaging
plate (BAS-SR, Fujifilm, Tokyo, Japan), and the radioactivity of
each section was determined using a bio-imaging analyzer
(BAS5000, Fujifilm). Another set of tissue sections adjacent to
those used for autoradiography was stained with TUNEL.
Statistical evaluation
A one-way analysis of variance (ANOVA) followed by Dunnett’s
post hoc test compared with the untreated control group was used
for the experiments of 5-FU chemotherapy and evaluation of
tumor uptake of 99mTc-C3(BHam)2-Annexin A5. Tumor uptake
between control group and 5-FU treated group after injection of
99mTc-C3(BHam)2-Annexin A5 was compared using Students’ t
test. Results of p,0.05 were considered statistically significant.
Results
Preparation of 99mTc-C3(BHam)2-annexin A5
C3(BHam)2-annexin A5 conjugate was prepared by converting
the amine group of NH2-C3(BHam)2 (1) into a maleimide group
with EMCS (2), followed by a conjugation reaction of the
maleimide group with the thiol group of Annexin A5 with 2-IT. By
Figure 1. Preparation of C3(BHam)2-annexin A5.
doi:10.1371/journal.pone.0081191.g001
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measuring the thiol groups, the number of C3(BHam)2 ligands
introduced per molecule of annexin A5 was estimated to be 0.7.
99mTc-C3(BHam)2-annexin A5 was prepared by a ligand exchange
reaction from 99mTc-glucoheptonate with radiochemical yields of
47-97% and radiochemical purity of over 95%.
Cell Binding Assay
In a cell binding assay to determine the bioactivity of 99mTc-
labeled annexin A5, the percentages of 99mTc-C3(BHam)2-annexin
A5 and 99mTc-HYNIC-annexin A5 bound to erythrocytes were
78.9260.63 and 81.3560.89, respectively. These values of both
types of 99mTc-labeled annexin A5 indicated that their bioactivities
are comparable.
Biodistribution Studies
Table 1 lists the biodistribution of 99mTc-C3(BHam)2-annexin
A5 and 99mTc-HYNIC-annexin A5 in normal mice. 99mTc-
C3(BHam)2-annexin A5 had remarkably lower kidney accumula-
tion of radioactivity than 99mTc-HYNIC-annexin A5. In the
organs for metabolism, such as liver and kidney, the radioactivity
of 99mTc-HYNIC-annexin A5 was residual for a long time. On the
other hand, radioactivity in these tissues after 99mTc-C3(BHam)2-
annexin A5 administration gradually decreased. However, the
Table 1. Comparative biodistribution of radioactivity at
10 min, 1, 3, and 6 h after injection of 99mTc-C3(BHam)2-
annexin A5 and 99mTc-HYNIC-annexin A5 in mice.
Tissue Time after injection
10 min 1 h 3 h 6 h
99mTc-C3(BHam)2-annexin A5
Blood 21.12 (1.86) 6.75 (0.45) 4.37 (0.38) 2.75 (0.33)
Liver 10.22 (1.33) 10.30 (1.82) 7.53 (0.56) 4.99 (0.61)
Kidney 34.84 (2.58) 32.14 (2.35) 16.05 (1.60) 10.25 (2.03)
Intestine 1.31 (0.07) 2.94 (0.53) 7.23 (0.69) 10.56 (0.62)
Spleen 9.07 (1.25) 13.49 (2.29) 10.76 (1.81) 5.58 (1.92)
Pancreas 1.16 (0.12) 1.22 (0.13) 1.07 (0.19) 0.65 (0.08)
Lung 13.19 (3.44) 7.88 (1.25) 5.08 (0.82) 2.83 (0.53)
Heart 6.64 (2.89) 4.16 (0.57) 2.94 (0.34) 1.64 (0.26)
Stomach{ 0.72 (0.05) 1.04 (0.20) 1.15 (0.31) 0.81 (0.16)
99mTc-HYNIC-annexin A5
Blood 3.39 (0.34) 0.51 (0.05) 0.29 (0.02) 0.19 (0.02)
Liver 4.58 (0.35) 6.01 (0.54) 5.99 (0.46) 6.21 (0.68)
Kidney 104.98 (12.47) 114.18 (13.32) 113.52 (16.39) 108.52 (12.83)
Intestine 0.85 (0.17) 0.77 (0.09) 1.10 (0.32) 1.56 (0.05)
Spleen 6.20 (0.75) 7.15 (0.96) 7.32 (0.42) 6.82 (2.12)
Pancreas 0.93 (0.11) 0.71 (0.26) 0.55 (0.09) 0.55 (0.07)
Lung 4.77 (0.26) 2.37 (0.41) 1.96 (0.36) 1.60 (0.53)
Heart 2.05 (0.32) 1.21 (0.17) 1.04 (0.07) 1.00 (0.19)
Stomach{ 0.37 (0.06) 0.45 (0.05) 0.49 (0.12) 0.57 (0.05)
Data are expressed as % injected dose per gram tissue. Each value represents
the mean (SD) of 4-5 mice.
{Data are expressed as % injected dose.
doi:10.1371/journal.pone.0081191.t001
Figure 2. Tumor grouth curves. Curves depicting inhibition of the
growth of colon-26 in treatment with 150 mg/kg of 5-FU (closed circles)
or 100 mg/kg of 5-FU (closed diamonds) compared with untreated
control group (open circles). Data are expressed as tumor volume
relative to that on the day of treatment (mean 6 SEM for 5 mice).
Significance was determined using one-way ANOVA followed by
Dunnett’s post hoc test (**p,0.01, *p,0.05 vs. control group).
doi:10.1371/journal.pone.0081191.g002
Figure 3. Tumore uptake. Comparison of tumor uptake of (A) 99mTc-
C3(BHam)2-annexin A5 (mean 6 SD for 4-6 mice) and (B)
99mTc-HYNIC-
annexin A5 (mean 6 SD for 6 mice) at 4 h after injection after 5-FU
treatment or non-treatment. In the case of 99mTc-C3(BHam)2-annexin
A5, significance was determined using one-way ANOVA followed by
Dunnett’s post hoc test (**p,0.01, *p,0.05 vs. control group). In the
case of 99mTc-HYNIC-annexin A5, significance was determined using
Students’ t test (*p,0.05 vs. control group).
doi:10.1371/journal.pone.0081191.g003
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blood clearance of 99mTc-C3(BHam)2-annexin A5 was slower
when compared with that of 99mTc-HYNIC-annexin A5. 99mTc-
C3(BHam)2-annexin A5 showed a higher initial uptake in liver
than 99mTc-HYNIC-annexin A5.
Tumor Accumulation of 99mTc-C3(BHam)2-annexin A5
and 99mTc-HYNIC-annexin A5 after Chemotherapy
Tumor volume as a function of time is shown in Figure 2. The
colon-26 tumor cells proliferated exponentially in the untreated
control group. In mice treated with 5-FU, especially the 150 mg/
kg dose injected group, tumor growth was significantly inhibited
compared to that of the untreated group. When 99mTc-
C3(BHam)2-annexin A5 was administered into tumor-bearing
mice after 24 h of the first 5-FU treatment (at 7 days after
inoculation), the accumulation of 99mTc-C3(BHam)2-annexin A5
in tumor tissue was significantly higher than that of the untreated
group (Figure 3A). The accumulation of 99mTc-HYNIC-annexin
A5 in tumor tissue was also significantly higher than in that of the
untreated group (Figure 3B). At the same time, the number of
TUNEL-positive cells in the tumor sections of the 5-FU-treated
group was greater than that of the untreated control group
(Figure 4). In both the case of 99mTc-HYNIC-annexin A5 and that
of 99mTc-C3(BHam)2-annexin A5, the values of percent injected
dose/gram in the tumor correlated well with the counts of
TUNEL-staining positive cells in corresponding tissue sections
(Figure 5).
Ex Vivo Autoradiographic Experiments
Autoradiographic images of tumoral sections at 4 hours after
injection of 99mTc-C3(BHam)2-annexin A5 and corresponding
TUNEL-staining images in adjacent sections are shown in
Figure 6. These images show that the accumulation of radioac-
tivity in tumors of 5-FU treated mice was higher compared to that
in non-treatment control mice. Moreover, the sites of higher
accumulation of radioactivity and the sites of intense positive
TUNEL staining seem to match. To investigate whether the
intratumoral localization of 99mTc-C3(BHam)2-annexin A5 corre-
lated with the sites of drug-induced apoptosis cells, we divided the
autoradiographic and TUNEL-staining images of tumor sections
using grids (grid size; 0.45 mm60.55 mm) and determined the
radioactivity and number of TUNEL-positive cells in each grid.
The results showed that the intratumoral accumulations of
radioactivity correlated well with the counts of TUNEL-staining
positive cells in corresponding grids (Figure 7).
Discussion
Tetradentate ligands, such as N3S and N2S2 coordination
molecules, form stable 99mTc complexes with the [Tc = O]3+ core.
Figure 4. TUNEL-stained images. Representative TUNEL-stained
images of tumor specimen in control mouse (A), 100 mg/kg of 5-FU-
treated mouse (B), and 150 mg/kg of 5-FU-treated mouse (C). Scale bar
= 100 mm.
doi:10.1371/journal.pone.0081191.g004
Figure 5. Correlation between TUNEL-positive cells and tumor
uptake. Correlation between the number of TUNEL-positive cells in
tumor after first 5-FU therapy and 99mTc-C3(BHam)2-annexin A5
accumulation (%dose/g) (A) or 99mTc-HYNIC-annexin A5 accumulation
(%dose/g) (B) in corresponding tumor tissue.
doi:10.1371/journal.pone.0081191.g005
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In the field of apoptosis imaging, a 99mTc complex with N2S2
ligand-conjugated annexin A5 had been developed and evaluated
in a previous paper [14,15]. However, most of these ligands could
require harsh conditions such as high pH or high temperature to
prepare 99mTc complexes with high radiochemical yields. Thus,
99mTc labeling of annexin A5 with a N2S2 ligand was performed
using the preformed chelate approach. This method requires
multiple steps and purification, resulting in a 25-30% overall
radiochemical yield [6]. In this study, we developed a new 99mTc-
labeled annexin A5, 99mTc-C3(BHam)2-annexin A5, using a
C3(BHam)2 ligand, which can form a
99mTc complex over a wide
pH range under mild reaction conditions. Actually, the
C3(BHam)2 ligand was introduced into annexin A5 before
radiolabeling, and 99mTc-C3(BHam)2-annexin A5 was prepared
with high radiochemical yields at room temperature, the same as
for 99mTc-HYNIC-annexin A5, which is a benchmark in the field
of apoptosis imaging in nuclear medicine.
The main purpose of the drug design of 99mTc-C3(BHam)2-
annexin A5 is the lower accumulation and faster clearance of
radioactivity from non-target tissues. It has been reported that
persistent radioactivity localization in tissues after injection of
[99mTc](HYNIC-polypeptide)(tricine)2 could be attributed to the
slow rate of elimination of the radiometabolite, [99mTc](HYNIC-
lysine)(tricine)2, from the lysosomes, due to the replacement of a
tricine as a coligand with high molecular weight proteins [16]. In
the biodistribution experiments in this study, 99mTc-HYNIC-
annexin A5 showed very high radioactivity in kidney; radioactivity
in the organs for metabolism, such as liver and kidney, was
retained for a long time (Table 1). In this case, the slow rate of
elimination of radiometabolite from 99mTc-HYNIC-annexin A5
might also affect the long retention of radioactivity in liver and
kidney. On the other hand, when 99mTc-C3(BHam)2-annexin A5
was administered to normal mice, the radioactivity in liver and
kidney decreased gradually over time. As we expected, this result
suggests that the radiometabolite of 99mTc-C3(BHam)2-annexin
A5 was not residual in the metabolic organs. However, after
administration of 99mTc-C3(BHam)2-annexin A5, the rate of blood
clearance was slower and the accumulation of radioactivity in liver
was higher than we expected. Introduction of the C3(BHam)2
ligand and linker might affect the biodistribution of annexin A5
although the bioactivity of 99mTc-C3(BHam)2-annexin A5 re-
mained. The slow blood clearance should hamper imaging soon
after injection of the radiotracer. However, it could enhance the
accumulation of the radiotracer at the lesion site. In a previous
study, the introduction of polyethylene glycol (PEG) into 111In-
labeled annexin A5 achieved increased uptake of and improved
visualization with the radiotracer in solid tumors after chemo-
therapy [17]. Actually, 99mTc-C3(BHam)2-annexin A5 showed
higher accumulation in the tumor after treatment of 5-FU
compared to 99mTc-HYNIC-annexin A5 (Figure 3) although it
may be not practival in this case because of the short half-life of
99mTc.
Figure 6. Autoradiography. Representative autoradiographic imag-
es (A, D) and TUNEL-staining images (B, C, E, F) for adjacent tumor
sections from mice treated with 5-FU (A, B, C) or non-treatment mice (D,
E, F). Scale bar = 1 mm.
doi:10.1371/journal.pone.0081191.g006
Figure 7. Correlation between TUNEL-positive cells and radio-
acitvity in tumor section. Correlation between the number of
TUNEL-positive cells in each grid (0.45 mm60.55 mm) of a tumoral
section and 99mTc-C3(BHam)2-annexin A5 accumulation (%dose) deter-
mined by autoradiography in each corresponding grid of an adjacent
section from mice treated with 5-FU (A) or non-treatment mice (B).
doi:10.1371/journal.pone.0081191.g007
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To determine whether 99mTc-C3(BHam)2-annexin A5 could
detect early response after chemotherapy, 5-FU treatment for
colon-26 tumor-bearing mice was performed. As a result, the
treatment with 5-FU inhibited tumor proliferation in a dose-
dependent manner (Figure 2). At the same time, 99mTc-
C3(BHam)2-annexin A5 accumulation in tumors 24 h after the
first 5-FU treatment was also significantly increased in a dose-
dependent manner compared to that of the untreated control
group (Figure 3A). At the same time, TUNEL staining, which
marks the degraded DNA in the cell, has been used as a marker for
apoptosis [18]. The number of TUNEL-positive cells in the tumor
sections of the 5-FU-treated groups was also greater than that of
the untreated control group (Figure 4), and was significantly
correlated with 99mTc-C3(BHam)2-annexin A5 uptake or
99mTc-
HYNIC-annexin A5 uptake in tumor tissue (Figure 5). These
results indicate that 99mTc-C3(BHam)2-annexin A5 and
99mTc-
HYNIC-annexin A5 could predict therapeutic effects just after the
start of 5-FU treatment before morphologic changes in tumor can
be observed. Furthermore, our results are consistent with a
previous report, which showed that tumor uptake of 99mTc-
HYNIC-annexin A5 increased significantly after a single dose of
cyclophosphamide treatment (150 mg/kg, i.p.) in KDH-8 hepa-
toma tumor-bearing rats, and the increase was concordant with
the number of TUNEL-positive cells in the tumor [19].
To investigate intratumoral distribution of 99mTc-C3(BHam)2-
annexin A5 and apoptotic cells, autoradiographic experiments and
TUNEL staining were performed using serial frozen sections of
tumor. Radioactivity and TUNEL-positive cells were heteroge-
neously distributed in the tumors, but the site of high accumulation
of 99mTc-C3(BHam)2-annexin A5 corresponded to the site of
intense TUNEL-staining (Figure 6), which was a similar result to a
previous report [17]. Moreover, the correlation between the
intratumoral accumulations of radioactivity by autoradiography
and the TUNEL-staining positive cells in corresponding sections
was strongly positive and significant (Figure 7). These results also
suggest that 99mTc-C3(BHam)2-annexin A5 accumulates in lesions
where apoptotic cells exist, that is to say, 99mTc-C3(BHam)2-
annexin A5 could be used to visualize apoptotic cells.
In conclusion, these findings suggest that 99mTc-C3(BHam)2-
annexin A5 may contribute to improved cell death imaging,
namely, be useful in the rapid and efficient detection of apoptotic
tumor response after chemotherapy.
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